BioCentury
ARTICLE | Company News

ImmunoGen cancer news

October 3, 2016 7:00 AM UTC

ImmunoGen will cut headcount by 65 (17%) to about 320 and seek to partner its non-core B cell lymphoma programs IMGN529 and coltuximab ravtansine ( SAR3419) to focus on developing its cancer antibody-drug conjugates (ADCs), including mirvetuximab soravtansine. The company expects the cuts, which will primarily come from technical operations and G&A functions, to save about $11 million annually. This quarter, ImmunoGen plans to begin the Phase III FORWARD I trial of mirvetuximab soravtansine, a folate receptor 1 ( FOLR1; FR-alpha)-targeting mAb linked to ImmunoGen’s DM4 cytotoxic agent, to treat FOLR1-positive platinum-resistant ovarian cancer. The company will also focus on developing its preclinical ADC assets IMGN632, an ADC targeting IL-3 receptor alpha ( CD123) for hematological malignancies; and IMGN779, an ADC consisting of Z4681A, a humanized anti- CD33 antibody, conjugated to DGN462, a DNA-alkylating indolino-benzodiazepin, for acute myelogenous leukemia (AML). Immunogen will report preclinical data for both compounds this year; clinical data for IMGN779 is expected in 2017. ...